OBJECTIVES: To report the effect of certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, on patient reported outcomes (PRO) in psoriatic arthritis (PsA), as investigated in RAPID-PsA (NCT01087788). METHODS: The ongoing 158 week (Wk) RAPID-PsA trial is double blind and placebo-controlled to Wk24. Recruited patients had active PsA and had failed ≥1 DMARD. Patients could have received 1 previous anti-TNF. Patients were randomized 1:1:1 to placebo, or 400mg CZP at Wk 0, 2 and 4 (loading dose) followed by either 200mg CZP every 2 weeks (Q2W) or 400mg CZP every 4 weeks (Q4W). PRO measures evaluated: fatigue assessment scale (FAS), patient assessment of pain (VAS), health assessment questionnaire-disability index (HAQ-DI), SF-36, PsAQoL, and the Dermatology Life Quality Index (DLQI). Change from baseline for PRO was analyzed for the randomized population, with LOCF imputation. RESULTS: A total of 409 patients were randomized. 20% of patients had received a prior anti-TNF. Baseline demographics were similar between groups. From baseline to Wk24, differences in pain (-11.2 vs. -28.6 and -28.4), fatigue (-0.6 vs. -2.2 and -1.9), HAQ-DI (-0.19 vs. -0.54 and -0.46), SF-36 physical component summary (2.14 vs. 8.43 and 7.58) and mental component summary (0.73 vs 5.49 and 3.49), PsAQoL (-1.27 vs. -4.43 and -3.30), and DLQI (-1.4 vs. -6.3 and -5.2) were observed in placebo vs. CZP 200mg Q2W and 400mg Q4W arms (p<0.001). Differences were observed from Wk1 and were irrespective of prior anti-TNF exposure. More patients on CZP reached SF-36 general population norms than placebo patients.  CONCLUSIONS: CZP effectively improved multiple PROs in PsA patients across many disease facets. The benefits of CZP treatment on physical and emotional components of HRQoL were seen across generic, PsA-specific and dermatology-specific measures. These benefits were seen in patients regardless of prior anti-TNF exposure.